ArticleScience China. Life sciences2026
A novel pathologic scoring system for predicting postoperative recurrence in BCLC stage 0-A hepatocellular carcinoma patients: a nationwide multicenter study.
Article in Science China. Life sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Mint3 suppresses cuproptosis by modulating the AHR signalling pathway to facilitate the progression of hepatocellular carcinoma.Science China. Life sciences · 2026Article
- Review Article: Biomarkers in Liver Transplantation for Hepatocellular Carcinoma: Towards Precision Medicine.Alimentary pharmacology & therapeutics · 2026Review
- Prognostic and therapeutic significance of microscopic tumor focus in combined hepatocellular-cholangiocarcinoma: a multicenter pathological study.Journal of gastrointestinal oncology · 2026Article
- Preoperative prediction of early recurrence and microvascular invasion in hepatocellular carcinoma using conventional ultrasound, elastography, and clinical nutritional indicators: a radiomics-based study.American journal of translational research · 2026Article
- A Preoperative MRI-Based Score to Predict High-Risk Pathology and Stratify Adjuvant Therapy Benefit in BCLC 0/A Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2026Article
- Integrative multiomics dissection of LSM7 as a prognostic biomarker and therapeutic target in hepatocellular carcinoma.Science progressArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
35 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to develop and validate a novel pathological scoring system, the MSE score (microvascular invasion, satellite foci, Edmondson-Steiner grade), for predicting postoperative recurrence in hepatocellular carcinoma (HCC) patients at BCLC stage 0-A following liver resection. The MSE score was compared to the established microvascular invasion/satellitosis (mVI/S) scoring system, which combines microvascular invasion and satellite nodules, both of which are significant predictors of aggressive recurrence and mortality. A total of 3,338 patients from 28 centers, who underwent curative liver resection between January 2017 and January 2020, were included. These patients were divided into a training cohort (n=2,337) and a validation cohort (n=1,001). Univariate and multivariate Cox regression models, along with Kaplan-Meier survival analysis, receiver operating characteristic (ROC) curves, and random forest modeling, were used to assess recurrence factors and compare predictive performance. The results showed that the MSE score had superior discriminatory power compared to mVI/S in predicting recurrence and overall survival. Kaplan-Meier analysis indicated a significantly better separation of low- and high-risk groups with the MSE score (P<0.001), while ROC analysis revealed higher AUC values for the MSE score at 1, 3, and 5 years. Multivariate Cox analysis demonstrated higher predictive power for the MSE score (HR=2.900 (1.808-4.652)) compared to mVI/S (HR=2.134 (1.567-3.043)). Additionally, logistic regression confirmed that the MSE score had stronger predictive power for aggressive recurrence (OR=2.992 (1.816-4.862) vs. mVI/S OR=1.847 (1.105-3.470)). SHAP analysis highlighted that the MSE score was more significant than mVI/S. The MSE score also outperformed traditional BCLC staging, TNM staging, and preoperative serum AFP levels in predicting recurrence. In conclusion, the MSE score provides reliable predictions for postoperative aggressive recurrence and survival in BCLC stage 0-A HCC, offering superior risk stratification compared to mVI/S and promising utility in guiding postoperative management.
Indexed as
Identifiers
40947464What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.